Contrarian Interest and Raised Guidance Collide with Valuation and Governance Risks

What happened

Birkenstock recently raised its fiscal outlook amid ongoing double-digit revenue growth and disclosed a sizable stake from a well-known contrarian investor, yet the stock has slid roughly 16% over the past year and hovers near its lows. The company's fundamentals remain strong: FY25 revenue grew 16% to €2.1 billion with adjusted EBITDA margin of 31.8%, driven by double-digit growth across all regions and a rising closed-toe mix. However, the market decline appears to reflect persistent risks that offset the positive news, including new U.S. tariffs on EU-made product, foreign exchange headwinds, and unresolved material weaknesses in internal controls. Moreover, despite the share-price drop, Birkenstock still trades at approximately 24 times trailing earnings and 17 times EV/EBITDA, which is nearly 80% above a conservative discounted cash flow estimate of $25.85 per share. The contrarian investor's disclosure may signal perceived value, but the DeepValue master report maintains a cautious WAIT stance, arguing that the current price embeds aggressive growth assumptions without a sufficient margin of safety.

Implication

For existing holders, the raised guidance and contrarian support are positive signals, but they do not negate the risks of margin compression from tariffs and FX, nor the governance concerns from unremediated internal control weaknesses. The current valuation, still rich relative to conservative intrinsic estimates, means that a sustained rebound likely requires flawless execution on capacity expansion, tariff pass-through, and control remediation. A pullback toward the mid-teens forward P/E or materially below the DCF reference would improve the risk-reward, while any evidence of brand fatigue or margin slippage would undermine the bull case. Investors should monitor quarterly reports for confirmation of double-digit growth despite tariffs, progress on internal controls, and deleveraging toward the target net leverage of 1.3-1.4x. Until such de-risking occurs or the price resets significantly, the prudent stance remains to wait for a more compelling entry point rather than chase the current rebound narrative.

Thesis delta

The news of raised guidance and a contrarian investor's stake slightly improves the sentiment backdrop but does not alter the core thesis that BIRK is a high-quality business at a price that offers insufficient margin of safety. The master report's WAIT stance remains appropriate; a shift to POTENTIAL BUY would require either a lower share price or tangible progress on tariff mitigation and control remediation. Conversely, any sign of growth deceleration or margin erosion would shift the stance to POTENTIAL SELL.